Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 19/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 19/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31433918 | 0.87 | DDB1 (0.41) | DDB1CRBN | |
| SCHEMBL25567327 | 0.81 | DDB1 (0.55) | DDB1CRBN | |
| SCHEMBL25862450 | 0.80 | DDB1 (0.50) | DDB1CRBN | |
| SCHEMBL31323635 | 0.79 | DDB1 (0.45) | DDB1CRBNIDO1 | |
| SCHEMBL26635830 | 0.77 | DDB1 (0.68) | DDB1CRBN | |
| SCHEMBL25857318 | 0.77 | DDB1 (0.48) | DDB1CRBN | |
| SCHEMBL25566682 | 0.77 | DDB1 (0.48) | DDB1CRBN | |
| SCHEMBL31433519 | 0.76 | DDB1 (0.37) | DDB1CRBN | |
| SCHEMBL31323447 | 0.75 | CRBN (0.46) | DDB1CRBN | |
| SCHEMBL26503079 | 0.74 | CRBN (0.47) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | DDB1 188/4885CRBN 3024/4885IDO1 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.